Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

PEGCETACOPLAN for C3 glomerulopathy: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 27 adverse event reports in the FDA FAERS database where PEGCETACOPLAN was used for C3 glomerulopathy.

Most Reported Side Effects for PEGCETACOPLAN

Side Effect Reports % Deaths Hosp.
Fatigue 135 9.9% 1 44
Visual impairment 125 9.1% 0 4
Haemoglobin decreased 106 7.7% 1 51
Haemolysis 100 7.3% 1 57
Off label use 97 7.1% 9 35
Vitreous floaters 78 5.7% 0 4
Breakthrough haemolysis 67 4.9% 1 18
Headache 66 4.8% 2 25
Product dose omission issue 59 4.3% 2 26
Uveitis 59 4.3% 0 0
Covid-19 56 4.1% 1 21
Vitritis 55 4.0% 0 5
Choroidal neovascularisation 52 3.8% 1 2
Eye inflammation 52 3.8% 0 2
Drug ineffective 49 3.6% 8 15

Other Indications for PEGCETACOPLAN

Paroxysmal nocturnal haemoglobinuria (559) Product used for unknown indication (352) Dry age-related macular degeneration (326) Age-related macular degeneration (23) Macular degeneration (13) Neovascular age-related macular degeneration (13)

Other Drugs Used for C3 glomerulopathy

ECULIZUMAB (267) MYCOPHENOLATE MOFETIL (126) RAVULIZUMAB-CWVZ (59) PREDNISONE (46) PREDNISOLONE (45) RITUXIMAB (34) BORTEZOMIB (28) DEXAMETHASONE (24) TACROLIMUS (23) IPTACOPAN (21)

Related Pages

PEGCETACOPLAN Full Profile All C3 glomerulopathy Drugs PEGCETACOPLAN Demographics PEGCETACOPLAN Timeline